Benzinga | Aug 18, 2021 08:57AM EDT

Cabaletta Bio's Cell Therapy Shows Encouraging Safety Profile In Autoimmune Skin Disorder

* Cabaletta Bio Inc (NASDAQ:CABA) has announced 28-day data from the second dose cohort from the DesCAARTes Phase 1 trial of DSG3-CAART for mucosal-dominant pemphigus vulgaris (mPV).

* Related: Cabaletta Announced Favorable Safety Profile From First Cohort Of Phase 1 Study.

* Patients received 100 million DSG3-CAART cells in the second cohort, a five-fold higher dose than the initial cohort.

* No clinically relevant adverse events or dose-limiting toxicities were observed.

* Similar to the first cohort, the safety profile was observed in the presence of circulating anti-DSG3 antibodies.

* The DesCAARTes trial has initiated dosing of patients in the third cohort at a treatment dose of 500 million DSG3-CAART cells.

* Cabaletta expects to announce top-line data on biologic activity from the first two cohorts and safety data from the 500 million dose cohort in Q4 of 2021.

* Absent DLTs in the third cohort, a fourth dose cohort using 2.5 billion cells will also initiate dosing in 2021.

* Price Action: CABA shares are up 1.21% at $7.50 during the premarket session on the last check Wednesday.